In this article, we will take a detailed look at the best low priced growth stocks to invest in.
Low priced stocks usually fall under the small to mid-cap size category. This growth criteria, often proxied through high double-digit revenue growth rate, helps narrow down the stock universe to a sample of relatively cheap stocks but with explosive growth potential that tend to perform well in periods of macroeconomic stability, low interest rates, and positive economic growth. The performance of value vs. growth stocks has been studied for decades, and most studies agree that value tends to outperform growth factors over long periods of time. For instance, Vanguard Research in a 2021 publication showed that value stocks in the US have outperformed growth in almost every single year since 1936 until the early 2010s, when a major shift occurred.
Vanguard Research argued that during the 10 years preceding the publication date, US growth stocks have outperformed US value stocks by an average of 7.8% per year, which is a significantly high difference. Such findings can be attributed to several technological developments in consumer electronics, media & communications, semiconductors, and AI, which fueled unprecedented productivity improvements and growth in new markets that generally fall under the growth category. This hypothesis is confirmed by Arnott et al. (2021) study, which claims that the success of growth stocks is primarily attributed to the technology companies that benefit from platform effects and the “winner-take-all” economics. Among other factors that drove the increasing outperformance of growth stocks are low inflation and prolonged periods of low interest rates during the 2010s and early 2020s.
READ ALSO: 10 Best Low Priced Technology Stocks To Buy Now
The last 3 years presented a very mixed picture in the growth vs. value dilemma. The year 2022 brought significant outperformance of value as rising interest rates and inflation slashed the potential of growth stocks. However, 2023 and the emergence of the AI megatrend brought a new growth frontier across the semiconductor and technology sectors, which sparked an unprecedented rise in stock market concentration and the relative outperformance of growth stocks. This rally lasted for exactly 2 years and ended just recently with the inauguration of the Trump 2.0 administration and its subsequent actions that shook the global markets. The US stock market is now down 20% from its February 2025 peak, meaning that growth stocks ceded back almost half of their gains made since 2023. This has been primarily driven by Trump 2.0 actions such as tariffs and public spending cuts that could fuel inflation, keep rates high, and limit GDP growth. This is an unfavorable environment for growth stocks.
However, despite the widespread fears, we believe that the stock market is at or near its bottom, and several potential developments in the following weeks could push stock prices higher and favor the low priced growth stocks again. First, there have been widespread news that the European Union and countries like India are actively seeking the possibility of negotiating free trade agreements with the USA, which points towards the scenario that Trump’s tariffs will be cancelled at some point, at least for the major trade partners. Second, any substantial economic slowdown that could be triggered by tariffs will very likely lead to the FED cutting interest rates and the US administration playing out some of their strong cards, such as corporate tax cuts. Third, the tariff threats will lead to a (partial) move of manufacturing back into the US, which is already slowly happening, as evidenced by total manufacturing employees increasing sequentially in both February and March. This argument is further reinforced by confirmed news that large foreign semiconductor fabs are seeking to expand their presence in the US and build several fabs. All in all, the key takeaway for the reader is that once the current correction is over, the growth factor will become favored again, and the best possible move for investors under such circumstances is to seek exposure to low priced growth stocks that we discuss below.
A businessperson giving a presentation on a graph demonstrating the growth of a mid-capitalization equity market.
Our Methodology
We screened the market and selected companies with a share price below $10.00 that achieved a revenue at a compound annual growth rate (CAGR) of at least 20% in the last 5 years. Then we compared the list with Insider Monkey’s proprietary database of hedge funds’ ownership and included in the article the top 10 companies with the largest number of hedge funds that own the stock as of Q4 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. Payoneer Global Inc. (NASDAQ:PAYO)
Revenue CAGR last 5 years: 25.68%
Stock price as of April 7th close: $6.18
Number of Hedge Fund Holders: 35
Payoneer Global Inc. (NASDAQ:PAYO) is a financial technology company that provides payment solutions for freelancers, online sellers, and small businesses specializing in ecommerce. The company’s competitive advantage consists of establishing a strong presence at lower volume brackets (the typical freelancer receiving his pay online), which may have difficulties with cross-border payments. PAYO’s platform supports transactions in more than 200 countries and also offers solutions for working capital management to help businesses grow.
Payoneer Global Inc. (NASDAQ:PAYO) delivered a record-breaking performance in 2024, with revenue growth excluding interest income accelerating to 20% (vs. 5% in the previous year). B2B volume grew 42% YoY, significantly outpacing the initial guidance of 25%. The company achieved three consecutive quarters of positive adjusted EBITDA, excluding interest income, demonstrating improved profitability if compared to the past. Customer adoption of 3 or more products reached 53% of total usage in Q4 2024, representing a 30% increase in less than 3 years.
Going forward, Payoneer Global Inc. (NASDAQ:PAYO) is focused on delivering sustained growth and profitability by refining its strategy, enhancing acquisition efficiency, increasing cross-selling, improving retention, and optimizing pricing. PAYO expanded its financial stack with the acquisition of Skuad, positioning itself to capture a share in global workforce management. For 2025, management expects 15% growth in revenue, excluding interest income, aligning with their previous medium-term targets. With an explosive 25.68% revenue CAGR in the last 5 years, PAYO is one of the best low priced stocks to consider.
9. Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Revenue CAGR last 5 years: 24.32%
Stock price as of April 7th close: $7.15
Number of Hedge Fund Holders: 40
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotechnology company engaged in developing treatments for rare diseases. Its primary products include “migalastat”, an oral therapy for adults with Fabry disease and amenable genetic variants, as well as drugs for adults with late-onset Pompe disease. FOLD’s advantage consists of extensive focus on R&D and the utilization of proprietary biotechnologies. With a global presence, the company is aiming to address unmet medical needs in the rare disease community.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) delivered strong financial results in 2024, with total revenue reaching $528 million, representing 32% growth YoY or 33% on a constant currency basis. Galafold product achieved revenue of $458 million with 18% growth YoY, while Pombiliti & Opfolda generated over $70 million globally. The company ended 2024 with more than 2,700 people taking Galafold for Fabry disease and 220 people being treated or scheduled for treatment with Pombiliti & Opfolda, which represents a significant expansion on a YoY basis.
Looking ahead, Amicus Therapeutics, Inc. (NASDAQ:FOLD) projects 17% to 24% total revenue growth at constant exchange rates for 2025, driven by Galafold’s growth of 10-15% and Pombiliti & Opfolda’s growth of 65-85%. Management anticipates that the company is well-positioned to surpass $1 billion in total sales in 2028, supported by geographic expansion with launches planned in up to 10 new markets next year. The company also achieved its goal of full-year non-GAAP profitability in 2024 and expects to deliver positive GAAP net income during 2H 2025. The company’s strong growth and potential to boost profitability in the years ahead secured its place on our list of best low priced stocks.
